Formosa Laboratories Inc
Formosa Laboratories, Inc., together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. The company offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulator… Read more
Formosa Laboratories Inc (4746) - Net Assets
Latest net assets as of September 2025: NT$8.56 Billion TWD
Based on the latest financial reports, Formosa Laboratories Inc (4746) has net assets worth NT$8.56 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$13.54 Billion) and total liabilities (NT$4.99 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$8.56 Billion |
| % of Total Assets | 63.18% |
| Annual Growth Rate | 13.28% |
| 5-Year Change | 63.59% |
| 10-Year Change | 149.75% |
| Growth Volatility | 16.7 |
Formosa Laboratories Inc - Net Assets Trend (2009–2024)
This chart illustrates how Formosa Laboratories Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Formosa Laboratories Inc (2009–2024)
The table below shows the annual net assets of Formosa Laboratories Inc from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$8.65 Billion | +5.32% |
| 2023-12-31 | NT$8.21 Billion | +5.31% |
| 2022-12-31 | NT$7.80 Billion | +2.55% |
| 2021-12-31 | NT$7.60 Billion | +43.82% |
| 2020-12-31 | NT$5.29 Billion | +18.59% |
| 2019-12-31 | NT$4.46 Billion | -2.21% |
| 2018-12-31 | NT$4.56 Billion | +11.14% |
| 2017-12-31 | NT$4.10 Billion | -0.07% |
| 2016-12-31 | NT$4.10 Billion | +18.53% |
| 2015-12-31 | NT$3.46 Billion | +14.07% |
| 2014-12-31 | NT$3.04 Billion | +20.65% |
| 2013-12-31 | NT$2.52 Billion | +50.25% |
| 2012-12-31 | NT$1.67 Billion | -10.93% |
| 2011-12-31 | NT$1.88 Billion | +34.92% |
| 2010-12-31 | NT$1.39 Billion | +4.57% |
| 2009-12-31 | NT$1.33 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Formosa Laboratories Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 570.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$2.23 Billion | 29.00% |
| Common Stock | NT$1.20 Billion | 15.65% |
| Other Comprehensive Income | NT$479.89 Million | 6.25% |
| Other Components | NT$3.77 Billion | 49.11% |
| Total Equity | NT$7.68 Billion | 100.00% |
Formosa Laboratories Inc Competitors by Market Cap
The table below lists competitors of Formosa Laboratories Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Taekwang Ind
KO:003240
|
$160.16 Million |
|
Nam Tai Property Inc.
PINK:NTPIF
|
$160.20 Million |
|
Elme Communities
NYSE:ELME
|
$160.21 Million |
|
UEM Sunrise Bhd
KLSE:5148
|
$160.21 Million |
|
Cellectis SA
NASDAQ:CLLS
|
$160.13 Million |
|
HKFoods Oyj A
HE:HKFOODS
|
$160.12 Million |
|
Mildef Crete
TWO:3213
|
$160.12 Million |
|
PASONA GROUP INC.
F:9D4
|
$160.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Formosa Laboratories Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,570,952,000 to 7,684,075,000, a change of 113,123,000 (1.5%).
- Net income of 157,268,000 contributed positively to equity growth.
- Dividend payments of 240,512,000 reduced retained earnings.
- Other comprehensive income decreased equity by 67,219,000.
- Other factors increased equity by 263,586,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$157.27 Million | +2.05% |
| Dividends Paid | NT$240.51 Million | -3.13% |
| Other Comprehensive Income | NT$-67.22 Million | -0.87% |
| Other Changes | NT$263.59 Million | +3.43% |
| Total Change | NT$- | 1.49% |
Book Value vs Market Value Analysis
This analysis compares Formosa Laboratories Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.87x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.50x to 0.87x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$36.96 | NT$55.30 | x |
| 2010-12-31 | NT$22.33 | NT$55.30 | x |
| 2011-12-31 | NT$27.91 | NT$55.30 | x |
| 2012-12-31 | NT$24.89 | NT$55.30 | x |
| 2013-12-31 | NT$35.14 | NT$55.30 | x |
| 2014-12-31 | NT$33.59 | NT$55.30 | x |
| 2015-12-31 | NT$36.60 | NT$55.30 | x |
| 2016-12-31 | NT$43.58 | NT$55.30 | x |
| 2017-12-31 | NT$42.27 | NT$55.30 | x |
| 2018-12-31 | NT$43.13 | NT$55.30 | x |
| 2019-12-31 | NT$43.57 | NT$55.30 | x |
| 2020-12-31 | NT$44.04 | NT$55.30 | x |
| 2021-12-31 | NT$60.87 | NT$55.30 | x |
| 2022-12-31 | NT$62.21 | NT$55.30 | x |
| 2023-12-31 | NT$62.83 | NT$55.30 | x |
| 2024-12-31 | NT$63.90 | NT$55.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Formosa Laboratories Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.32%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.81x
- Recent ROE (2.05%) is below the historical average (7.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 16.96% | 11.90% | 1.12x | 1.27x | NT$92.68 Million |
| 2010 | 17.70% | 9.84% | 1.06x | 1.70x | NT$107.29 Million |
| 2011 | 12.29% | 8.80% | 0.84x | 1.66x | NT$43.08 Million |
| 2012 | 0.30% | 0.20% | 0.63x | 2.41x | NT$-162.43 Million |
| 2013 | -2.76% | -2.81% | 0.50x | 1.98x | NT$-320.97 Million |
| 2014 | 8.65% | 10.52% | 0.44x | 1.87x | NT$-41.03 Million |
| 2015 | 8.16% | 10.87% | 0.40x | 1.86x | NT$-63.83 Million |
| 2016 | 11.78% | 15.16% | 0.47x | 1.64x | NT$73.08 Million |
| 2017 | 5.94% | 9.40% | 0.35x | 1.80x | NT$-163.29 Million |
| 2018 | 4.01% | 6.58% | 0.31x | 1.98x | NT$-263.91 Million |
| 2019 | -0.94% | -1.49% | 0.29x | 2.20x | NT$-477.24 Million |
| 2020 | 7.69% | 13.01% | 0.30x | 1.98x | NT$-120.47 Million |
| 2021 | 16.89% | 39.75% | 0.26x | 1.62x | NT$509.57 Million |
| 2022 | 2.88% | 5.76% | 0.30x | 1.70x | NT$-535.25 Million |
| 2023 | 1.67% | 2.90% | 0.32x | 1.80x | NT$-630.85 Million |
| 2024 | 2.05% | 3.32% | 0.34x | 1.81x | NT$-611.14 Million |
Industry Comparison
This section compares Formosa Laboratories Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,528,453,600
- Average return on equity (ROE) among peers: 3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Formosa Laboratories Inc (4746) | NT$8.56 Billion | 16.96% | 0.58x | $160.16 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |